Default company panoramic image


InnaVirVax is developing at the clinical stage an innovating therapy for HIV infection that will act in synergy with antiretrovirals.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Évry, IDF, France
  • Currency EUR
  • Founded March 2008
  • Employees 10
  • Website

Company Summary

InnaVirVax, incorporated in 2008, is a French biopharmaceutical company. Its most advanced project is an innovative therapy for HIV infection that has completed a Phase I/IIa clinical trial and been found to be safe and well tolerated. This therapy would act in synergy with antiretrovirals, reducing the morbity and mortality of this disease. At peak sales, it is expected yearly worth is expected to be more than €1 billion.


  • Default avatar
    Joël CROUZET
    Chief Executive Officer & Chairman of the Board

    Joel Crouzet, PhD, co-founder of InnaVirVax, with 20 years of experience in R&D, was Director of Research at Neurotech and AP Cells, and Departmental Director at Rhône-Poulenc Rorer (Sanofi Aventis). He invented two patents that are now in industrial use. He gained experience in business development as General Manager at Inserm-Transfert, and has received awards from Rhône-Poulenc, the French Academy of Sciences and the French Senate.

  • Default avatar
    Chief Medical Officer

    Shahin Gharakhanian MD, DTM&H, Dip.PH specializes in HIV medicine and infectious diseases. Until recently, he was Vice-President of Vertex Pharmaceuticals Inc., Medicines Development Group, Global R&D. During his career, his jobs have ranged from the General Manager of a full-service Contract Research Organization to Program Executive leading product development, regulatory approval/launch, and has thus gain extensive expertise in these areas.

  • Default avatar
    Nathalie BARAN
    Operation Development Manager

    Nathalie holds an MBA and has a PhD in endocrinology. She has gained experience if start-up development while working for several yeaNathalie Baran holds an MBA and a PhD in endocrinology. She gained experience of start-up development while working for several years at OSEO, the French Innovation Agency, and Genopole Entreprises, a Paris-region incubator. Her expertise lies in finance, grant raising and business development.

  • Default avatar
    Raphael HO TSONG FANG
    Clincial Operation Manager

    Raphaël Ho Tsong Fang, DVM & PhD in microbiology and medical virology, has worked for eight years on SIV (Simian ImmunoDeficiency Virus) and HIV infections at the Pasteur Institute in Paris and at UCLA, Los Angeles where he gained considerable knowledge of HIV disease and pathogenesis. He also has expertise in the non-clinical assessment of vaccines. He has actively participated to the development of VAC-3S at InnaVirVax.

  • Default avatar
    Dominique BATEJAT
    Head of Pharmaceutical Development

    Dominique Batéjat, Ms has expertise in biochemistry, molecular biology and pharmaceutical development. Her industrial experience includes working for Cellectis and Nautilus Biotech.


  • Default avatar
    Frédéric Lerner, SCP Lerner Friggeri & Associés
    Default avatar
    In Extenso

Previous Investors

  • Default avatar
    Cap Decisif Management
    Default avatar
    G1J Ile-de-France, Fonds Régional de Co-Investissement, FaDièse
    Default avatar
    Pradeyrol Développement